REG - Shield Therapeutics - Block listing 6 Monthly Return

Shield TherapeuticsAnnouncement

02/01/2026 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260102:nRSB4870Na&default-theme=true

RNS Number : 4870N  Shield Therapeutics PLC  02 January 2026

 

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Block Listing 6 Monthly Return

 

  Name of applicant:                                                               SHIELD THERAPEUTICS PLC

 Name of scheme:                                                                   Shield Therapeutics Retention Share Plan
 Period of return:                        From:                                    01 July 2025    To:             31 December 2025
 Balance of unallotted securities under scheme(s) from previous return:            39,794
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         NIL
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        39,794

 

 Name of applicant:                                                                SHIELD THERAPEUTICS PLC

 Name of scheme:                                                                   Shield Therapeutics plc 2016 Company Share Option Plan
 Period of return:                        From:                                    01 July 2025         To:                  31 December 2025
 Balance of unallotted securities under scheme(s) from previous return:            341,020
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         NIL
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        341,020

 

 

  Name of applicant:                                                               SHIELD THERAPEUTICS PLC

 Name of scheme:                                                                   The Shield Therapeutics plc 2016 Long Term Incentive Plan
 Period of return:                        From:                                    01 July 2025          To:                   31 December 2025
 Balance of unallotted securities under scheme(s) from previous return:            24,273
 Plus:  The amount by which the block scheme(s) has been increased since the       NIL
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         NIL
 (see LR3.5.7G):
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        24,273

 

 

 

 

 

 Name of applicant:                                                                SHIELD THERAPEUTICS PLC
 Name of scheme:                                                                   Shield Therapeutics Retention and Performance Share Plan
 Period of return:                        From:                                    01 July 2025         To:                  31 December 2025
 Balance of unallotted securities under scheme(s) from previous return:            2,870,838
 Plus:  The amount by which the block scheme(s) has been increased since the       15,000,000
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period         6,137,791
 (see LR3.5.7G):

 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        11,733,071

 

 Name of contact:              Lucy Huntington-Bailey
 Telephone number of contact:  +44 (0) 191 511 8500

 

For further information please contact:

 

 Shield Therapeutics plc                                                                        www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Anders Lundstrom, CEO                                                                          +44 (0) 191 511 8500

 Santosh Shanbhag, CFO                                                                          info@shieldtx.com

 Lucy Huntington-Bailey, Company Secretary

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel/Christoper Golden                                                                  +44 (0)20 7418 8900
 Joint Broker

 Cavendish Ltd

 Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet
 Ward

                                                                                                +44 (0)20 7220 0500

 

About Iron Deficiency and ACCRUFeR®/FeRACCRU®

Clinically low iron levels (aka iron deficiency, ID) can cause serious health
problems for adults of all ages, across multiple therapeutic areas. Together,
ID and ID with anemia (IDA) affect about 20 million people in the US and
represent a $2.3B market opportunity. As the first and only FDA approved oral
iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet
medical need for both physicians and patients and is now the leading #1
branded prescription oral iron the market today (data source - IQVIA Xponent
PlanTrak).

 

ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral
therapy for adults with ID/IDA. The drug has a novel mechanism of absorption
compared to other oral iron therapies and has been shown to be an efficacious
and well-tolerated therapy in a range of clinical trials. More information
about ACCRUFeR®/FeRACCRU®, including the product label, can be found at:
www.accrufer.com (http://www.accrufer.com) and www.feraccru.com
(http://www.feraccru.com) .

 

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company that delivers
ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated
pharmaceutical product, to address a significant unmet need for patients
suffering from iron deficiency, with or without anemia. The Company has
launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration
agreement with Viatris. Outside of the U.S., the Company has licensed the
rights to five specialty pharmaceutical companies. FeRACCRU® is
commercialised in the UK and European Union by Norgine B.V., which also has
marketing rights in Australia and New Zealand. FeRACCRU® is also
commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an
exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd.,
for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China,
Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of
Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc.
for Japan.

 

ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.

ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLREAFFAEESKEFA



            Copyright 2019 Regulatory News Service, all rights reserved